7.32
                                            전일 마감가:
              $7.25
            열려 있는:
              $7.28
            하루 거래량:
                5.72M
            Relative Volume:
              1.35
            시가총액:
                $1.54B
            수익:
              $557.51M
            순이익/손실:
              $-35.71M
            주가수익비율:
              -40.67
            EPS:
                -0.18
            순현금흐름:
                $15.50M
            1주 성능:
              +1.67%
            1개월 성능:
              -3.56%
            6개월 성능:
                -17.29%
            1년 성능:
              -8.61%
            바이오크리스트 Stock (BCRX) Company Profile
명칭
                  
                      Biocryst Pharmaceuticals Inc
                    
                전화
                  
                      919-859-1302
                    
                주소
                  
                      4505 EMPEROR BOULEVARD, DURHAM, NC
                    
                BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 | 
|---|---|---|---|---|---|---|
|   
                          
                                BCRX
                            
                             Biocryst Pharmaceuticals Inc | 7.32 | 1.53B | 557.51M | -35.71M | 15.50M | -0.18 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 | 
|---|---|---|---|
| 2025-10-15 | 재개 | TD Cowen | Buy | 
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line | 
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight | 
| 2025-02-25 | 개시 | Wedbush | Outperform | 
| 2023-11-20 | 재개 | JP Morgan | Overweight | 
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform | 
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy | 
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy | 
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy | 
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform | 
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line | 
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform | 
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight | 
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral | 
| 2021-12-10 | 개시 | Oppenheimer | Outperform | 
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold | 
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight | 
| 2021-03-01 | 개시 | Cowen | Outperform | 
| 2020-09-29 | 재개 | JP Morgan | Overweight | 
| 2020-06-17 | 개시 | BTIG Research | Neutral | 
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight | 
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy | 
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform | 
| 2018-11-16 | 재개 | Piper Jaffray | Overweight | 
| 2018-08-08 | 재개 | JP Morgan | Overweight | 
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral | 
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral | 
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform | 
| 2017-12-20 | 개시 | Barclays | Equal Weight | 
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform | 
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight | 
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy | 
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy | 
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight | 
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform | 
| 2016-02-09 | 재확인 | FBR Capital | Outperform | 
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral | 
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold | 
                    모두보기
                     
                  
                바이오크리스트 주식(BCRX)의 최신 뉴스
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyGlobal Markets & Reliable Intraday Trade Plans - newser.com
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackEarnings Miss & Daily Profit Focused Stock Screening - newser.com
Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Momentum Check & Smart Swing Trading Techniques - newser.com
Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutEarnings Risk Summary & Real-Time Price Movement Reports - newser.com
Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Short Interest & Verified Technical Signals - newser.com
Will BioCryst Pharmaceuticals Inc. stock attract ESG investorsMarket Sentiment Summary & Fast Exit/Entry Strategy Plans - newser.com
Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolutionWeekly Stock Recap & Reliable Intraday Trade Alerts - newser.com
# BioCryst’s SWOT analysis: stock positioned for growth amid HAE market expansion - Investing.com
BioCryst Pharmaceuticals (BCRX) Price Target Increased by 19.59% to 21.51 - Nasdaq
BioCryst Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Why BioCryst Shares Plunged - AOL.com
Aug Shorts: Why hedge funds are buying BioCryst Pharmaceuticals Inc. stockTrade Entry Report & Weekly Stock Performance Updates - Fundação Cultural do Pará
When is the best time to exit BioCryst Pharmaceuticals Inc.July 2025 Snapshot & Free Low Drawdown Momentum Trade Ideas - newser.com
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - sharewise.com
Will BioCryst Pharmaceuticals Inc. stock outperform international peersPortfolio Update Report & AI Optimized Trading Strategy Guides - Fundação Cultural do Pará
BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Monday - MarketBeat
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오크리스트 주식 (BCRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 | 
|---|---|---|---|---|---|---|---|
| HEGGIE THERESA | Director | Aug 13 '25 | Sale | 8.51 | 70,000 | 595,868 | 65,352 | 
                자본화:
                 
                  | 
                볼륨(24시간):
                 
            
         
                     
                             Stockscreener 앱 받기
                    Stockscreener 앱 받기